Linked Data API

Show Search Form

Search Results

1084387
registered interest false more like this
date less than 2019-03-08more like thismore than 2019-03-08
answering body
Department for Business, Energy and Industrial Strategy more like this
answering dept id 201 more like this
answering dept short name Business, Energy and Industrial Strategy more like this
answering dept sort name Business, Energy and Industrial Strategy more like this
hansard heading Drugs: Research more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Business, Energy and Industrial Strategy, with reference to the August 2017 Life sciences: industrial strategy report, what recent assessment he has made of the adequacy of the process of translating academic discovery into industry drug development in (a) immunology, (b) genomics and (c) other areas where the UK is world-leading. more like this
tabling member constituency Hornsey and Wood Green remove filter
tabling member printed
Catherine West more like this
uin 230083 more like this
answer
answer
is ministerial correction false more like this
date of answer remove filter
answer text <p>The sector’s Life Science Industrial Strategy, authored by Professor Sir John Bell, made recommendations to government in support of the vision for the UK to be a global hub that makes the UK the home of clinical research and medical innovation. The two Life Sciences Sector Deals are collaborative endeavours across government, academia, charities and industry to deliver on this bold vision.</p><p>The two Deals include significant joint investment from government and the sector to support research and development, both academic and commercial, to ensure the UK remains at the forefront of global drug development.</p><p>The UK has a track record of supporting university spin out companies, with the goal of translating innovative research into commercial successes and ultimately treatments that will benefit patients. Catalyst programmes, including Innovate UK and the Medical Research Council’s Biomedical Catalyst aim to de-risk innovative science and commercialise ideas arising out of academia and industry, helping UK SMEs to develop into competitive and sustainable organisations.</p><p>The Government recently announced further support for genomics as part of my rt. hon. Friend Mr Chancellor of the Exchequer’s Spring Statement. The announcement featured a £45 million investment for increasing the European Bioinformatics Institute’s computing and storage capacity which underpins much of the UK’s genomics research work, including UK Biobank. This announcement supports the boosting the UK’s genomics sector, which is a key commitment in our second Life Sciences Sector Deal.</p>
answering member constituency Kingswood more like this
answering member printed Chris Skidmore more like this
question first answered
less than 2019-03-25T15:11:11.727Zmore like thismore than 2019-03-25T15:11:11.727Z
answering member
4021
label Biography information for Chris Skidmore more like this
tabling member
4523
label Biography information for Catherine West more like this